melagatran has been researched along with metoclopramide in 4 studies
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (metoclopramide) | Trials (metoclopramide) | Recent Studies (post-2010) (metoclopramide) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 5,044 | 1,216 | 623 |
| Protein | Taxonomy | melagatran (IC50) | metoclopramide (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 2.383 | |
| Myeloperoxidase | Homo sapiens (human) | 0.35 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.721 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.127 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 7.8 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 3.675 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 2.383 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 7.8 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.2 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.88 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.63 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6237 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.88 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
4 other study(ies) available for melagatran and metoclopramide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |